Infectious Diseases, published by TAYLOR & FRANCIS LTD, is a leading academic journal dedicated to advancing research in the field of infectious diseases and microbiology. With an impressive impact factor and categorized in Q1 in multiple areas including Immunology and Microbiology, this journal serves as a critical platform for researchers, practitioners, and students to disseminate their findings and stay abreast of current advancements. The journal is recognized for its rigorous peer-review process and aims to foster innovation and collaboration across disciplines from 2015 to 2024. It boasts a robust Scopus ranking, positioning it favorably among the top-tier of journals in the relevant fields, making it an essential resource for anyone involved in infectious disease research. Access options are available, ensuring that the latest research is accessible to a global audience, thus emphasizing the journal's commitment to promoting knowledge and understanding in the ever-evolving landscape of infectious diseases.

Microbial Drug Resistance, published by MARY ANN LIEBERT, INC, is a pivotal journal that explores the critical intersection of microbiology and pharmacology with a keen focus on antibiotic resistance and related issues. Since its inception in 1995, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for innovative studies that inform the global response to antimicrobial resistance. With a commendable position in the Category Quartiles, ranked Q2 in Medicine (miscellaneous) and Q2 in Pharmacology for 2023, it caters to a multidisciplinary audience by addressing the implications of microbial resistance within various medical contexts. Although currently non-Open Access, the journal allows subscribers and institutions to access high-quality, peer-reviewed research, directly impacting policy and practice in healthcare settings. Committed to advancing our understanding and combating the challenges posed by resistant microbes, Microbial Drug Resistance remains an essential publication in the fields of microbiology, immunology, and pharmacology.

Infection and Chemotherapy, an esteemed journal published by the Korean Society of Antimicrobial Therapy, focuses on the dynamic fields of infectious diseases and pharmacology. With an ISSN of 2093-2340 and an E-ISSN of 2092-6448, this peer-reviewed, open-access journal has been providing a crucial platform for research dissemination since 2008. Based in South Korea, it boasts a significant impact in the academic community, as evidenced by its Q2 ranking in both Infectious Diseases and Pharmacology categories for 2023. It holds a Scopus rank of 64 out of 272 in Pharmacology and 98 out of 344 in Infectious Diseases, showcasing its prominence and the quality of research it publishes. With a focus on advancing scientific knowledge, Infection and Chemotherapy is committed to fostering essential dialogues among researchers, clinicians, and students, making it a vital resource for those engaged in the fight against infectious diseases and the development of effective therapeutic protocols.

CLINICAL MICROBIOLOGY AND INFECTION is a leading journal published by Elsevier Science Ltd, dedicated to advancing the field of infectious diseases and clinical microbiology. With its ISSN 1198-743X and E-ISSN 1469-0691, this esteemed journal has maintained its influential presence since 1995, showcasing high-impact research that addresses critical issues in the diagnosis, treatment, and prevention of infections. Ranked in the Q1 quartile for Infectious Diseases, Medicine (miscellaneous), and Microbiology (medical) categories, and boasting impressive Scopus rankings of #12 and #7 respectively, it sits at the forefront of scientific inquiry in these disciplines. Although it is not an Open Access journal, it provides comprehensive access options for institutions and individuals, ensuring the dissemination of vital research findings. As the field of clinical microbiology continues to evolve, CLINICAL MICROBIOLOGY AND INFECTION remains an essential resource for researchers, clinicians, and students aiming to stay informed on the latest developments and breakthroughs in understanding infectious diseases.

Emerging Infectious Diseases, published by the Centers for Disease Control and Prevention, is a leading open-access journal that has been dedicated to the field of epidemiology, infectious diseases, and medical microbiology since its inception in 1995. With an impressive impact factor placing it in the Q1 quartile rankings for multiple categories including Epidemiology, Infectious Diseases, and Medical Microbiology, this journal serves as a vital resource for researchers, practitioners, and students dedicated to combating the challenges posed by emerging infectious diseases. The journal's distinguished Scopus ranks further highlight its global influence, ranking #10 in Epidemiology, #26 in Infectious Diseases, and #13 in Medical Microbiology, all within the top percentiles. Accessible and targeted, Emerging Infectious Diseases publishes seminal research and reviews that contribute to the understanding and management of infectious diseases, ensuring that critical insights reach a broad audience. The journal encourages contributions that advance the scientific community’s knowledge and responses to public health challenges.

Indian Journal of Medical Microbiology, published by Elsevier, is a pivotal peer-reviewed journal dedicated to the field of medical microbiology, providing a vital platform for research and scholarship since its inception in 1986. With an Open Access model established in 2001, it ensures the dissemination of scientific knowledge to a global audience, enhancing accessibility for researchers, professionals, and students alike. The journal's scope spans critical areas including immunology, infectious diseases, and microbiology, with an impressive trajectory marked by converged years of publication allowing for a comprehensive exploration of evolving scientific trends. As of 2023, the journal holds a Q3 ranking in Infectious Diseases and Microbiology (medical) and a Q4 ranking in Immunology and Microbiology categories, reflecting its significant yet growing impact in the field. Researchers seeking to contribute to or stay updated on the latest advancements in medical microbiology will find the Indian Journal of Medical Microbiology a valuable resource, as it consistently bridges the gap between emerging science and clinical application.

Reviews and Research in Medical Microbiology is a premier academic journal published by LIPPINCOTT WILLIAMS & WILKINS, focusing on groundbreaking research and comprehensive reviews that advance the understanding of medical microbiology. With an ISSN of 2770-3150 and an E-ISSN of 2770-3169, this journal serves as an essential resource for researchers, healthcare professionals, and students dedicated to the study of pathogens, infectious diseases, and microbial mechanisms affecting health. While the journal currently does not offer open access, its rigorous peer-review process ensures that only high-quality, impactful research is disseminated to the scientific community. The journal aims to bridge gaps in knowledge by presenting cutting-edge studies that explore novel therapeutic strategies, diagnostic methods, and the evolving landscape of microbial resistance. Nestled in the heart of Philadelphia, this journal proudly contributes to the advancement of medical microbiology and is an indispensable platform for the publication of critical findings that shape clinical practices and research trajectories in the field.

New Microbes and New Infections is an esteemed peer-reviewed journal published by Elsevier Sci Ltd that has been a prominent platform for disseminating groundbreaking research in the fields of Infectious Diseases and Microbiology since its establishment in 2013. With an impressive Open Access model, this journal ensures that vital research findings are readily accessible to researchers, healthcare professionals, and academics worldwide. Positioned in the Q2 category for Infectious Diseases and Q3 for Microbiology in 2023, it reaches a significant global audience, as demonstrated by its high Scopus rankings—#44 out of 344 in Medicine: Infectious Diseases, and #34 out of 182 in Immunology and Microbiology. The journal aims to inspire new ideas and foster collaborations by publishing high-quality research focused on novel microbes and infections, thus playing a crucial role in advancing science and public health in an era where understanding infectious agents is more vital than ever.

JOURNAL OF INFECTION is a premier academic publication in the fields of infectious diseases and medical microbiology, published by W B SAUNDERS CO LTD. With a profound impact factor and established since 1979, this journal serves as a crucial resource for researchers, clinicians, and policy-makers seeking to advance knowledge and understanding of infectious processes and their management. The JOURNAL OF INFECTION holds an impressive position in the academic hierarchy as reflected by its Q1 quartile rankings in both Infectious Diseases and Microbiology (medical) for 2023, further underscored by its Scopus rankings: #2 in Medical Microbiology and #5 in Medical Infectious Diseases, placing it in the 98th percentile overall. While the journal does not offer Open Access options, it provides a comprehensive outlet for innovative research, reviews, and clinical insights that drive the field forward. Published from the United Kingdom, it attracts a global readership keen on staying at the forefront of infectious disease research, making it an essential addition to any academic and clinical library.

Expert Review of Anti-Infective Therapy, published by Taylor & Francis Ltd, is a leading journal in the field of infectious diseases, microbiology, and virology, boasting an impressive impact factor and ranking in the Q1 category across multiple disciplines. With an ISSN of 1478-7210 and E-ISSN 1744-8336, this journal has become a vital resource for researchers, professionals, and students aiming to advance their understanding of anti-infective therapies. Since its inception in 2003, the journal has provided critical insights, evidence-based reviews, and forward-thinking perspectives that contribute significantly to the ongoing efforts in combating infectious diseases. As of 2023, it ranks #36 out of 344 in Medicine/Infectious Diseases and maintains high percentiles in various other categories, reflecting its influence and reach within the scientific community. Although not an Open Access journal, its rich content is delivered through various academic libraries, sustaining its commitment to disseminating knowledge in the face of global health challenges. For those committed to innovation in the field, the Expert Review of Anti-Infective Therapy offers a platform that blends thorough research with practical applications, making significant strides in the fight against infectious pathogens.